Novel investigational vascular endothelial growth factor (VEGF) receptor antagonists for psoriasis

References

• Christophers E. Psoriasis–epidemiology and clinical spectrum. Clin Exp Dermatol. 2001;26(4):314–320.
   PubMed Web of Science ®Google Scholar
• Rapp SR, Feldman SR, Exum ML, et al. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol. 1999;41(3 Pt 1):401–407.
   PubMed Web of Science ®Google Scholar
• Armstrong AW, Harskamp CT, Armstrong EJ. Psoriasis and metabolic syndrome: a systematic review and meta-analysis of observational studies. J Am Acad Dermatol. 2013;68(4):654–662.
   PubMed Web of Science ®Google Scholar
• Weidemann AK, Crawshaw AA, Byrne E, et al. Vascular endothelial growth factor inhibitors: investigational therapies for the treatment of psoriasis. Clin Cosmet Investig Dermatol. 2013;6:233–244.
   PubMedGoogle Scholar
• Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet. 2007;370(9583):263–271.
   PubMed Web of Science ®Google Scholar
• Barker JN. The pathophysiology of psoriasis. Lancet (London, England). 1991;338(8761):227–230.
   PubMed Web of Science ®Google Scholar
• Lowes MA, Bowcock AM, Krueger JG. Pathogenesis and therapy of psoriasis. Nature. 2007;445(7130):866–873.
   PubMed Web of Science ®Google Scholar
• Detmar M, Brown LF, Claffey KP, et al. Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasis. J Exp Med. 1994;180(3):1141–1146.
   PubMed Web of Science ®Google Scholar
• Young HS, Summers AM, Bhushan M, et al. Single-nucleotide polymorphisms of vascular endothelial growth factor in psoriasis of early onset. J Invest Dermatol. 2004;122(1):209–215.
   PubMed Web of Science ®Google Scholar
• Hernández GL, Volpert OV, Iñiguez MA, et al. Selective inhibition of vascular endothelial growth factor-mediated angiogenesis by cyclosporin A: roles of the nuclear factor of activated T cells and cyclooxygenase 2. J Exp Med. 2001;193(5):607–620.
   PubMed Web of Science ®Google Scholar
• Markham T, Mullan R, Golden-Mason L, et al. Resolution of endothelial activation and down-regulation of Tie2 receptor in psoriatic skin after infliximab therapy. J Am Acad Dermatol. 2006;54(6):1003–1012.
   PubMed Web of Science ®Google Scholar
• Deng H, Yan C-L, Hu Y, et al. Photochemotherapy inhibits angiogenesis and induces apoptosis of endothelial cells in vitro. Photodermatol Photoimmunol Photomed. 2004;20(4):191–199.
   PubMed Web of Science ®Google Scholar
• Meissner M, Doll M, Hrgovic I, et al. Suppression of VEGFR2 expression in human endothelial cells by dimethylfumarate treatment: evidence for anti-angiogenic action. J Invest Dermatol. 2011;131(6):1356–1364.
   PubMed Web of Science ®Google Scholar
• García-Caballero M, Marí-Beffa M, Medina MÁ, et al. Dimethylfumarate inhibits angiogenesis in vitro and in vivo: a possible role for its antipsoriatic effect?. J Invest Dermatol. 2011;131(6):1347–1355.
   PubMed Web of Science ®Google Scholar
• Xia YP, Li B, Hylton D, et al. Transgenic delivery of VEGF to mouse skin leads to an inflammatory condition resembling human psoriasis. Blood. 2003;102(1):161–168.
   PubMed Web of Science ®Google Scholar
• Kerr DJ. Targeting angiogenesis in cancer: clinical development of bevacizumab. Nat Clin Pract Oncol. 2004;1(1):39–43.
   PubMedGoogle Scholar
• Kubota Y. Tumor angiogenesis and anti-angiogenic therapy. Keio J Med. 2012;61(2):47–56.
   PubMedGoogle Scholar
• Folkman J, Shing Y. Angiogenesis. J Biol Chem. 1992;267(16):10931–10934.
   PubMed Web of Science ®Google Scholar
• Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev. 2004;25(4):581–611.
   PubMed Web of Science ®Google Scholar
• Kiselyov A, Balakin KV, Tkachenko SE. VEGF/VEGFR signalling as a target for inhibiting angiogenesis. Expert Opin Investig Drugs. 2007;16(1):83–107.
   PubMed Web of Science ®Google Scholar
• Shinkaruk S, Bayle M, Laïn G, et al. Vascular endothelial cell growth factor (VEGF), an emerging target for cancer chemotherapy. Curr Med Chem Anti-Cancer Agents. 2003;3(2):95–117.
   PubMedGoogle Scholar
• Houck KA, Leung DW, Rowland AM, et al. Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. J Biol Chem. 1992;267(36):26031–26037.
   PubMed Web of Science ®Google Scholar
• Clauss M, Gerlach M, Gerlach H, et al. Vascular permeability factor: a tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration. J Exp Med. 1990;172(6):1535–1545.
   PubMed Web of Science ®Google Scholar
• Ferrara N, Gerber H-P, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003;9(6):669–676.
   PubMed Web of Science ®Google Scholar
• Takahashi S. Vascular endothelial growth factor (VEGF), VEGF receptors and their inhibitors for antiangiogenic tumor therapy. Biol Pharm Bull. 2011;34(12):1785–1788.
   PubMed Web of Science ®Google Scholar
• Bhushan M, McLaughlin B, Weiss JB, et al. Levels of endothelial cell stimulating angiogenesis factor and vascular endothelial growth factor are elevated in psoriasis. Br J Dermatol. 1999;141(6):1054–1060.
   PubMed Web of Science ®Google Scholar
• Creamer D, Allen M, Jaggar R, et al. Mediation of systemic vascular hyperpermeability in severe psoriasis by circulating vascular endothelial growth factor. Arch Dermatol. 2002;138(6):791–796.
   PubMedGoogle Scholar
• Brogan IJ, Khan N, Isaac K, et al. Novel polymorphisms in the promoter and 5’ UTR regions of the human vascular endothelial growth factor gene. Hum Immunol. 1999;60(12):1245–1249.
   PubMed Web of Science ®Google Scholar
• Watson CJ, Webb NJ, Bottomley MJ, et al. Identification of polymorphisms within the vascular endothelial growth factor (VEGF) gene: correlation with variation in VEGF protein production. Cytokine. 2000;12(8):1232–1235.
   PubMed Web of Science ®Google Scholar
• Young HS, Summers AM, Read IR, et al. Interaction between genetic control of vascular endothelial growth factor production and retinoid responsiveness in psoriasis. J Invest Dermatol. 2006;126(2):453–459.
   PubMed Web of Science ®Google Scholar
• Andrys C, Borska L, Pohl D, et al. Angiogenic activity in patients with psoriasis is significantly decreased by Goeckerman’s therapy. Arch Dermatol Res. 2007;298(10):479–483.
   PubMed Web of Science ®Google Scholar
• Chen H, Li X, Tang R. Effects of narrow band ultraviolet B on serum levels of vascular endothelial growth factor and interleukin-8 in patients with psoriasis. Am J Ther. 2015 Aug 24. PMID: 26308328. [Epub ahead of print].
   Google Scholar
• Akman A, Dicle O, Yilmaz F, et al. Discrepant levels of vascular endothelial growth factor in psoriasis patients treated with PUVA, Re-PUVA and narrow-band UVB. Photodermatol Photoimmunol Photomed. 2008;24(3):123–127.
   PubMed Web of Science ®Google Scholar
• Matsumura Y, Ananthaswamy HN. Short-term and long-term cellular and molecular events following UV irradiation of skin: implications for molecular medicine. Expert Rev Mol Med. 2002;4(26):1–22.
   PubMedGoogle Scholar
• Bielenberg DR, Bucana CD, Sanchez R, et al. Molecular regulation of UVB-induced cutaneous angiogenesis. J Invest Dermatol. 1998;111(5):864–872.
   PubMed Web of Science ®Google Scholar
• Liu Y, Yang G, Zhang J, et al. Anti-TNF-alpha monoclonal antibody reverses psoriasis through dual inhibition of inflammation and angiogenesis. Int Immunopharmacol. 2015;28(1):731–743.
   PubMed Web of Science ®Google Scholar
• Wen J, Wang X, Pei H, et al. Anti-psoriatic effects of Honokiol through the inhibition of NF-kappaB and VEGFR-2 in animal model of K14-VEGF transgenic mouse. J Pharmacol Sci. 2015;128(3):116–124.
   PubMed Web of Science ®Google Scholar
• Korpanty G, Smyth E. Anti-VEGF strategies – from antibodies to tyrosine kinase inhibitors: background and clinical development in human cancer. Curr Pharm Des. 2012;18(19):2680–2701.
   PubMed Web of Science ®Google Scholar
• Veritti D, Sarao V, Lanzetta P. Neovascular age-related macular degeneration. Ophthalmologica Journal international d’ophtalmologie Int J Ophthalmol Zeitschrift fur Augenheilkunde. 2012;227(Suppl 1):11–20.
   Web of Science ®Google Scholar
• Keshtgarpour M, Dudek AZ. SU-011248, a vascular endothelial growth factor receptor-tyrosine kinase inhibitor, controls chronic psoriasis. Transl Res. 2007;149(3):103–106.
   PubMed Web of Science ®Google Scholar
• Akman A, Yilmaz E, Mutlu H, et al. Complete remission of psoriasis following bevacizumab therapy for colon cancer. Clin Exp Dermatol. 2009;34(5):e202–e204.
   PubMed Web of Science ®Google Scholar
• Fournier C, Tisman G. Sorafenib-associated remission of psoriasis in hypernephroma: case report. Dermatol Online J. 2010;16(2):17.
   PubMedGoogle Scholar
• Narayanan S, Callis-Duffin K, Batten J, et al. Improvement of psoriasis during sunitinib therapy for renal cell carcinoma. Am J Med Sci. 2010;339(6):580–581.
   PubMed Web of Science ®Google Scholar
• Datta-Mitra A, Riar NK, Raychaudhuri SP. Remission of psoriasis and psoriatic arthritis during bevacizumab therapy for renal cell cancer. Indian J Dermatol. 2014;59(6):632.
   PubMed Web of Science ®Google Scholar
• Manning G, Whyte DB, Martinez R, et al. The protein kinase complement of the human genome. Science (New York, NY). 2002;298(5600):1912–1934.
   Google Scholar
• Imai K, Takaoka A. Comparing antibody and small-molecule therapies for cancer. Nat Rev Cancer. 2006;6(9):714–727.
   PubMed Web of Science ®Google Scholar
• Morabito A, Piccirillo MC, Falasconi F, et al. Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions. Oncologist. 2009;14(4):378–390.
   PubMed Web of Science ®Google Scholar
• Rock EP, Goodman V, Jiang JX, et al. Food and drug administration drug approval summary: Sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma. Oncologist. 2007;12(1):107–113.
   PubMed Web of Science ®Google Scholar
• Mendel DB, Laird AD, Xin X, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res. 2003;9(1):327–337.
   PubMed Web of Science ®Google Scholar
• Presta LG, Chen H, O’Connor SJ, et al.. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 1997;57(20):4593–4599.
   PubMed Web of Science ®Google Scholar
• Cohen MH, Gootenberg J, Keegan P, et al. FDA drug approval summary: bevacizumab plus FOLFOX4 as second-line treatment of colorectal cancer. Oncologist. 2007;12(3):356–361.
   PubMed Web of Science ®Google Scholar
• Saeed MU, Gkaragkani E, Ali K. Emerging roles for antiangiogenesis factors in management of ocular disease. Clin Ophthalmol (Auckland, NZ). 2013;6:533–543.
   PubMedGoogle Scholar
• Summers J, Cohen MH, Keegan P, et al. FDA drug approval summary: bevacizumab plus interferon for advanced renal cell carcinoma. Oncologist. 2010;15(1):104–111.
   PubMed Web of Science ®Google Scholar
• Khakoo AY, Kassiotis CM, Tannir N, et al. Heart failure associated with sunitinib malate: a multitargeted receptor tyrosine kinase inhibitor. Cancer. 2008;112(11):2500–2508.
   PubMed Web of Science ®Google Scholar
• Di Lorenzo G, Autorino R, Bruni G, et al. Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis. Ann Oncol. 2009;20(9):1535–1542.
   PubMed Web of Science ®Google Scholar
• Telli ML, Witteles RM, Fisher GA, et al. Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate. Ann Oncol. 2008;19(9):1613–1618.
   PubMed Web of Science ®Google Scholar
• Schmidinger M, Zielinski CC, Vogl UM, et al. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2008;26(32):5204–5212.
   PubMed Web of Science ®Google Scholar
• Zhu X, Wu S, Dahut WL, et al. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis. 2007;49(2):186–193.
   PubMed Web of Science ®Google Scholar
• Van Heeckeren WJ, Sanborn SL, Narayan A, et al. Complications from vascular disrupting agents and angiogenesis inhibitors: aberrant control of hemostasis and thrombosis. Curr Opin Hematol. 2007;14(5):468–480.
   PubMed Web of Science ®Google Scholar
• Kunstfeld R, Hirakawa S, Hong Y-K, et al.. Induction of cutaneous delayed-type hypersensitivity reactions in VEGF-A transgenic mice results in chronic skin inflammation associated with persistent lymphatic hyperplasia. Blood. 2004;104(4):1048–1057.
   PubMed Web of Science ®Google Scholar
• Halin C, Fahrngruber H, Meingassner JG, et al. Inhibition of chronic and acute skin inflammation by treatment with a vascular endothelial growth factor receptor tyrosine kinase inhibitor. Am J Pathol. 2008;173(1):265–277.
   PubMed Web of Science ®Google Scholar
• Schonthaler HB, Huggenberger R, Wculek SK, et al. Systemic anti-VEGF treatment strongly reduces skin inflammation in a mouse model of psoriasis. Proc Natl Acad Sci USA. 2009;106(50):21264–21269.
   PubMed Web of Science ®Google Scholar
• Jung K, Lee D, Lim HS, et al. Double anti-angiogenic and anti-inflammatory protein Valpha targeting VEGF-A and TNF-alpha in retinopathy and psoriasis. J Biol Chem. 2011;286(16):14410–14418.
   PubMed Web of Science ®Google Scholar
• Holash J, Davis S, Papadopoulos N, et al. VEGF-trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA. 2002;99(17):11393–11398.
   PubMed Web of Science ®Google Scholar
• Stewart MW, Grippon S, Kirkpatrick P. Aflibercept. Nat Rev Drug Discov. 2012;11(4):269–270.
   PubMed Web of Science ®Google Scholar
• Aggarwal C, Somaiah N, Simon G. Antiangiogenic agents in the management of non-small cell lung cancer: where do we stand now and where are we headed?. Cancer Biol Ther. 2012;13(5):247–263.
   PubMed Web of Science ®Google Scholar
• Tarhini AA, Frankel P, Margolin KA, et al. Aflibercept (VEGF trap) in inoperable stage III or stage iv melanoma of cutaneous or uveal origin. Clin Cancer Res. 2011;17(20):6574–6581.
   PubMed Web of Science ®Google Scholar
• Wang T-F, Lockhart AC. Aflibercept in the treatment of metastatic colorectal cancer. Clin Med Insights Oncol. 2012;6:19–30.
   PubMedGoogle Scholar
• Witte L, Hicklin DJ, Zhu Z, et al. Monoclonal antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an anti-angiogenic therapeutic strategy. Cancer Metastasis Rev. 1998;17(2):155–161.
   PubMed Web of Science ®Google Scholar
• Zenz R, Eferl R, Kenner L, et al. Psoriasis-like skin disease and arthritis caused by inducible epidermal deletion of Jun proteins. Nature. 2005;437(7057):369–375.
   PubMed Web of Science ®Google Scholar
• Agosta E, Lazzeri S, Orlandi P, et al. Pharmacogenetics of antiangiogenic and antineovascular therapies of age-related macular degeneration. Pharmacogenomics. 2012;13(9):1037–1053.
   PubMed Web of Science ®Google Scholar